合并淋巴瘤和糖尿病患者的生存情况及血糖控制：一项病例对照分析。
Survival and glycemic control in patients with coexisting lymphoma and diabetes: a case-control analysis.
作者信息
Rice Bria J, Buras Matthew R, Kosiorek Heidi E, Coppola Kyle E, Amin Shailja B, Verona Patricia M, Cook Curtiss B, Karlin Nina J
机构信息
Department of Internal Medicine, Mayo Clinic, Scottsdale, AZ 85259, USA.
Department of Biostatistics, Mayo Clinic, Scottsdale, AZ 85259, USA.
出版信息
Future Sci OA. 2020 Oct 27;7(1):FSO641. doi: 10.2144/fsoa-2020-0100.
AIM
We examined the effect of diabetes on survival in patients with lymphoma and the effect of lymphoma on glycemic control.
PATIENTS & METHODS: Patients with lymphoma with and without diabetes (2005-2016) were retrospectively identified and matched 1:1. Overall survival and progression-free survival were estimated by the Kaplan-Meier method. Hemoglobin A (HbA) and glucose levels during the year after cancer diagnosis were compared by mixed models.
RESULTS
For patients with diabetes, mean HbA during the year after lymphoma diagnosis was 6.7%. Estimated 5-year progression-free survival for patients with versus without diabetes was 63% (95% CI: 53-76%) versus 58% (95% CI: 46-71%) (p = 0.42).
CONCLUSION
Lymphoma and its treatment did not affect glycemic control. Diabetes did not decrease lymphoma-specific survival.
目的
我们研究了糖尿病对淋巴瘤患者生存的影响以及淋巴瘤对血糖控制的影响。
患者与方法
回顾性确定2005年至2016年患有和未患有糖尿病的淋巴瘤患者，并进行1:1匹配。采用Kaplan-Meier法估计总生存期和无进展生存期。通过混合模型比较癌症诊断后一年内的血红蛋白A（HbA）和血糖水平。
结果
对于糖尿病患者，淋巴瘤诊断后一年内的平均HbA为6.7%。患有糖尿病与未患有糖尿病患者的估计5年无进展生存期分别为63%（95%CI：53-76%）和58%（95%CI：46-71%）（p = 0.42）。
结论
淋巴瘤及其治疗不影响血糖控制。糖尿病不会降低淋巴瘤特异性生存率。
Zotero 插件